Biggest News Aggregation in the World
๐Ÿ“ฐ Redsa News

Page 2 - Redsa News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Redsa. Real-time updates on events, politics, business and more.

Head to Head Review: Edesa Biotech (NASDAQ:EDSA) versus Lexaria Bioscience (NASDAQ:LEXX)

Edesa Biotech (NASDAQ:EDSA – Get Free Report) and Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Insider & Institutional Ownership 31.3% of Edesa […]
British Columbia Lexaria Bioscience Lexaria Bioscience Corp Edesa Biotech Inc Yissum Research Development Company Edesa Biotech

Edesa Biotech (NASDAQ:EDSA) Price Target Cut to $21.00 by Analysts at HC Wainwright

Edesa Biotech (NASDAQ:EDSA – Free Report) had its price target lowered by HC Wainwright from $70.00 to $21.00 in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Edesa Biotech’s Q4 2023 earnings at ($0.73) EPS, FY2023 earnings at […]
Renaissance Technologies Cm Management Edesa Biotech Inc Cibc World Market Inc Millennium Management Edesa Biotech

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

MMDA official suspended over EDSA bus lane fiasco

MANILA, Philippines: Metropolitan Manila Development Authority (MMDA) Task Force Special Operations Chief Edison Bong Nebrija was suspended starting Thursday to ensure a fair investigation into reports in which he alleged that one of the vehicles that were apprehended along the EDSA Carousel Bus Lane belonged to Sen. Ramon Bong Revilla Jr.
Metropolitan Manila Philippines General Edison Bong Nebrija Romando Artes Ramon Bong Revilla Jr Metro Manila Council

Edesa Biotech (NASDAQ:EDSA) Given "Buy" Rating at Brookline Capital Management

Edesa Biotech (NASDAQ:EDSA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Brookline Capital Management in a research report issued on Thursday, Benzinga reports. They currently have a $57.00 price target on the stock. Separately, HC Wainwright decreased their price target on shares of Edesa Biotech from $112.00 to […]
Millennium Management Cibc World Market Inc Cm Management Renaissance Technologies Edesa Biotech Inc Edesa Biotech

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science